Movement Alert｜Luye Pharma Rises 5.29% in Regular Trading, Convertible Bond Redemption and Clinical Progress Fuel Rally

Market Focus07-14

On July 14, Luye Pharma rose 5.29% in regular trading, trading at HK$2.19/share, with turnover of HK$95.30 million.

On the news front, the company completed early redemption of all outstanding $180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, the company previously completed issuance of $180 million 5.25% convertible bonds due 2031, successfully executing a debt swap that reduced financing costs by 100 basis points.

Additionally, the company's self-developed first-in-class drug LY03015, a VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase 2 clinical results in China, meeting the primary endpoint with a 76.5% response rate at the highest dose — nearly double historical data for current first-line treatments. Merchants Securities maintained a Strong Buy rating, citing plans to advance LY03015 into Phase 3 trials in both China and the U.S.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187892603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187892603","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Luye Pharma Rises 5.29% in Regular Trading, Convertible Bond Redemption and Clinical Progress Fuel Rally","media":"Market Focus","content":"<p><p>On July 14, Luye Pharma rose 5.29% in regular trading, trading at HK$2.19/share, with turnover of HK$95.30 million.</p><p>On the news front, the company completed early redemption of all outstanding $180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, the company previously completed issuance of $180 million 5.25% convertible bonds due 2031, successfully executing a debt swap that reduced financing costs by 100 basis points.</p><p>Additionally, the company's self-developed first-in-class drug LY03015, a VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase 2 clinical results in China, meeting the primary endpoint with a 76.5% response rate at the highest dose — nearly double historical data for current first-line treatments. Merchants Securities maintained a Strong Buy rating, citing plans to advance LY03015 into Phase 3 trials in both China and the U.S.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Luye Pharma Rises 5.29% in Regular Trading, Convertible Bond Redemption and Clinical Progress Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Luye Pharma Rises 5.29% in Regular Trading, Convertible Bond Redemption and Clinical Progress Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, Luye Pharma rose 5.29% in regular trading, trading at HK$2.19/share, with turnover of HK$95.30 million.</p><p>On the news front, the company completed early redemption of all outstanding $180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, the company previously completed issuance of $180 million 5.25% convertible bonds due 2031, successfully executing a debt swap that reduced financing costs by 100 basis points.</p><p>Additionally, the company's self-developed first-in-class drug LY03015, a VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase 2 clinical results in China, meeting the primary endpoint with a 76.5% response rate at the highest dose — nearly double historical data for current first-line treatments. Merchants Securities maintained a Strong Buy rating, citing plans to advance LY03015 into Phase 3 trials in both China and the U.S.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1187892603","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187892603","pubTimestamp":1783995359,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, Luye Pharma rose 5.29% in regular trading, trading at HK$2.19/share, with turnover of HK$95.30 million.On the news front, the company completed early redemption of all outstanding $180...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"动向提醒|绿叶制药常规交易涨5.29%，可转债赎回和临床进展推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"On July 14, Luye Pharma rose 5.29% in regular trading, trading at HK$2.19/share, with turnover of HK$95.30 million.On the news front, the company completed early redemption of all outstanding $180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, the company previously completed issuance of $180 million 5.25% convertible bonds due 2031, successfully executing a debt swap that reduced financing costs by 100 basis points.Additionally, the company's self-developed first-in-class drug LY03015, a VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase 2 clinical results in China, meeting the primary endpoint with a 76.5% response rate at the highest dose — nearly double historical data for current first-line treatments. Merchants Securities maintained a Strong Buy rating, citing plans to advance LY03015 into Phase 3 trials in both China and the U.S.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187892603","isCrawlerRequest":true}